Immune system (system-level paracrine modulation by Umbilical Cord-derived Mesenchymal Stem Cells in combination with Disease-Modifying Anti-Rheumatic Drugs) (UC-MSC/DMARD therapy)

The 'Immune system – system-level paracrine modulation by UC-MSCs in combination with DMARDs' refers to a therapeutic strategy rather than a single molecular target. This approach utilizes the immunomodulatory properties of Umbilical Cord-derived Mesenchymal Stem Cells (UC-MSCs) to enhance the efficacy of conventional Disease-Modifying Anti-Rheumatic Drugs (DMARDs) in treating autoimmune conditions like rheumatoid arthritis (Wang et al., 2013). UC-MSCs function by sensing inflammatory signals and secreting paracrine factors such as indoleamine 2,3-dioxygenase (IDO), prostaglandin E2 (PGE2), and various cytokines that shift the immune environment from a pro-inflammatory to an anti-inflammatory state (Gao et al., 2021). This modulation primarily affects the balance of T-cell subsets, specifically increasing regulatory T cells (Tregs) while suppressing Th17 and Th1 cells. By combining these cells with DMARDs, clinicians aim to achieve a synergistic effect that restores systemic immune homeostasis and induces long-term remission in patients who are non-responsive to standard therapies. This system-level intervention targets the complex network of immune interactions rather than a single receptor or enzyme (Shi et al., 2018).

Other names

UC-MSC paracrine immunomodulationMesenchymal stem cell and DMARD combination therapySystemic immune modulation by MSCsUC-MSC/DMARD synergy

The mechanism involves the synergistic action of UC-MSCs and DMARDs to reset the immune system. UC-MSCs secrete paracrine factors such as TGF-β1, IL-10, and PGE2, which induce the expansion of CD4+CD25+Foxp3+ regulatory T cells (Tregs) and inhibit the differentiation of Th17 cells (Wang et al., 2013). DMARDs like methotrexate further suppress inflammatory pathways, together reducing the production of pro-inflammatory cytokines like TNF-α and IL-6, thereby restoring systemic immune tolerance (Gao et al., 2021).